Molecular Diagnostics News and Research

RSS

Myriad Genetics presents positive results of new hereditary cancer test at 36th annual conference of NSGC

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors in Columbus, OH.

18 Sep 2017

BWH researchers identify new rare genetic cause of peritoneal mesothelioma

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic radiation and, more recently, an inherited genetic mutation.

14 Sep 2017

DNAe announces pipeline of genomic-based tests for everyday workflow of physicians and hospitals

DNAe, the inventor of next generation semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its CBO, Nick McCooke presented an update on its first product, the LiDia bloodstream infections (BSI) test, and outlined DNAe’s pipeline of genomic-based tests at BioCentury’s 24th Annual Newsmakers in the Biotech Industry.

14 Sep 2017

Prostate Cancer Awareness Month: Myriad Genetics working to educate public about hereditary cancer risk assessment

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.

11 Sep 2017

Myriad Genetics introduces new precision medicine tool to enhance myRisk Hereditary Cancer test

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore, a new clinically validated precision medicine tool to enhance its myRisk Hereditary Cancer test. riskScore quantifies a woman's risk of developing breast cancer by combining genetic markers throughout the genome with her family and clinical history.

7 Sep 2017

New method of genetic testing leads to successful targeting of MET fusion in lung cancer

There are many ways a gene can be altered and there are many genes that, when altered, can cause cancer. Testing individually for each possible alteration in every cancer-related gene is not feasible as it would require hundreds of individual tests and many, many thousands of dollars.

31 Aug 2017

Understanding the rise in NTM infections

It is important to keep in mind that nontuberculous mycobacteria are environmental, and so unlike mycobacterial tuberculosis, generally this is not a person to person transmitted disease. The organisms are found universally in water and soil and so most people are exposed on a daily basis.

16 Aug 2017

Researchers develop and validate new assay that detects gene fusions in solid tumors

An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

14 Aug 2017

Highly sensitive blood test holds potential for quickly tracking cancer growth and spread

Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.

14 Aug 2017

New guidelines may lead to better management of patients with glioma

A University of Portsmouth academic has helped to develop European guidelines to treat brain tumors more effectively.

10 Aug 2017

ITL Group to celebrate 40 years of med-tech innovation at AACC

ITL Group’s global operation will be front and centre at the 69th Annual Scientific Meeting and Clinical Lab, from 29 July to 3 August in San Diego, California, marking its first appearance in 15 years.

From Vitl Life Science Solutions 1 Aug 2017

Siemens Healthineers- Siemens unveils new brand name for healthcare business

Today Siemens Healthcare unveiled its new brand name Siemens Healthineers. The new brand underlines Siemens Healthcare’s pioneering spirit and its engineering expertise in the healthcare industry.

From Siemens Healthineers Point of Care Diagnostics 26 Jul 2017

DiaSorin and Tecan partner to develop new platform for molecular diagnostics applications

DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent Laboratory Automation Solution as its nucleic acid extraction platform.

From Tecan 5 Jul 2017

New 10-minute test uses drops of blood or saliva for early detection of cancers

Researchers at Ram Group's Israeli bio-sensor division have developed a new molecular diagnostics test for early detection of cancers that takes just ten minutes and uses just a couple drops of blood or saliva.

24 Jun 2017

Alinity: the future of diagnostics?

Diagnostic tests are critical as up to 60 to 70% of critical clinical decisions are influenced by diagnostic test results. It's of huge importance to the running of any healthcare system. Here at Abbott, we believe that providing clinicians with quick access to diagnostics information and insights can help them make quick clinical decisions around the appropriate treatment for a patient,

From Abbott Diagnostics 14 Jun 2017

New OpenArray system offers simultaneous detection of pathogens in blood samples

The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.

From Thermo Fisher Scientific - Microbiology 13 Jun 2017

Roche to showcase new solutions for lab innovation at EuroMedLab

Roche announced today that it will be showcasing new solutions for lab innovation and leadership at the 22nd IFCC–EFLM European Congress of Clinical Chemistry and Laboratory Medicines in Athens, Greece, 11–15 June.

From Roche Sequencing and Life Science 13 Jun 2017

Prolaris becomes first genetic test to receive Medicare coverage for favorable intermediate and low-risk prostate cancer

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination to expand Medicare coverage of the Prolaris test.

29 May 2017

Study identifies potent molecular mechanism for insecticide resistance in sandfly species

A study led by LSTM identifies a potent molecular mechanism for insecticide resistance in the world's most medically-important sandfly species and develops DNA-diagnostics for monitoring future impact on visceral leishmaniasis control and elimination programs.

5 May 2017

Myriad and Clovis ink deal on FDA-approved BRACAnalysis CDx test to identify patients with germline BRCA mutations for rucaparib treatment

Myriad Genetics, Inc. and Clovis Oncology, Inc. have announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.

3 May 2017